In a statement, Merck said that the Lancet study was not comprehensive or new.
"Merck was vigilant in monitoring and disclosing the cardiovascular safety of Vioxx, and we absolutely disagree with any implication to the contrary.
Additionally, Standard &amp; Poor's placed Merck on CreditWatch with negative implications, which sends a strong signal that the company's debt could be downgraded within the next three months.
When Merck withdrew Vioxx, S&amp;P lowered its outlook to negative from stable.
The additional, more serious step taken Monday reflects the momentum in the Vioxx litigation and the delay in launching Arcoxia, Vioxx's successor drugs, said
